Kairos Pharma Ltd (KAPA) Stock Price, Quote & News

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology

Sector: Healthcare

Phone: 310-948-2356

Website: kairospharma.com

Address:

2355 Westwood Boulevard, Suite 139, Los Angeles, United States

Xtracked Dec. 28 at 11:21 PM

$KAPA

0 · Reply

Xtracked Dec. 28 at 11:16 PM

$KAPA

0 · Reply

JornelP Dec. 27 at 5:57 PM

$KAPA I'm thinking of starting a position here, listening to the science and KOL opinions sound great, but the company itself I'm finding issues with, and maybe just the situation they're in. So we have a possible banger waiting on Phase 2 data release, sub dollar PPS, no dilutions since April? What is burn rate, dilution risk when data drops, and how will they fund a phase 3 which can run 20 mil? Any answers appreciated thanks!

1 · Reply

StrawberryRips Dec. 26 at 6:24 PM

A blessed year for most of my swings. Short algos ruined a lot of the momentum this year tho… God bless the bulls 🙏 $IXHL $NCNA $KAPA $GLSI

1 · Reply

Xtracked Dec. 26 at 3:43 PM

$KAPA This should not be under $1... Phase 1 lung data? DUE Bank presentation cancelled 11/11, due to GOOD NEWS. Well let's hear the good news instead of letting top investors bleed!!! It somehow always benefits the big fish...total BS and should be handled

2 · Reply

Xtracked Dec. 26 at 1:15 PM

$KAPA Complain to the CEO....please Give him a call directly - 310 729 3371

1 · Reply

Stocktwits182182 Dec. 24 at 3:21 PM

$KAPA Soon, the only thing that's going to matter is how many shares you're holding.

1 · Reply

Tonyboner Dec. 23 at 7:54 PM

$KAPA This gets bought at some stage

0 · Reply

TB85 Dec. 23 at 7:13 PM

$KAPA Seems like Grinchen, came before Santa!🥴

0 · Reply

ezcheezie Dec. 23 at 1:50 PM

$KAPA Not the news we wanted. EOY right? ⌚👀

0 · Reply

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

Nov 4, 2025, 8:00 AM EST - 7 weeks ago

Kairos Pharma Provides Shareholder Update

Oct 20, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Oct 7, 2025, 8:00 AM EDT - 2 months ago

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Sep 18, 2025, 8:00 AM EDT - 3 months ago

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Sep 11, 2025, 8:00 AM EDT - 3 months ago

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 3, 2025, 8:15 AM EDT - 4 months ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 2, 2025, 4:05 PM EDT - 4 months ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Jul 28, 2025, 12:28 PM EDT - 5 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 16, 2025, 8:30 AM EDT - 5 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 15, 2025, 2:08 PM EDT - 5 months ago

Why Is Kairos Pharma Stock Surging On Tuesday?

Jul 15, 2025, 8:00 AM EDT - 5 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jun 3, 2025, 8:15 AM EDT - 7 months ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 6, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma, Ltd. Announces Participation in the D.

Apr 28, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 8 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 17, 2025, 8:00 AM EDT - 9 months ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Mar 31, 2025, 7:00 AM EDT - 9 months ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 27, 2025, 4:05 PM EDT - 9 months ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 20, 2025, 7:30 AM EDT - 10 months ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Feb 26, 2025, 7:00 AM EST - 10 months ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 18, 2025, 8:30 AM EST - 11 months ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 11, 2025, 8:30 AM EST - 11 months ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 6, 2025, 8:30 AM EST - 11 months ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Jan 28, 2025, 8:15 AM EST - 11 months ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 21, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 7, 2025, 8:15 AM EST - 1 year ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Dec 26, 2024, 7:51 AM EST - 1 year ago

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Dec 16, 2024, 12:15 PM EST - 1 year ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 3, 2024, 8:30 AM EST - 1 year ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Nov 26, 2024, 8:30 AM EST - 1 year ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 21, 2024, 2:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

BIOA BKV FBGL GLE GRDN LGCY PRB

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Feb 14, 2024, 6:16 PM EST - 2 years ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Oct 3, 2023, 3:33 PM EDT - 2 years ago

Kairos Pharma Files For U.S. IPO

Xtracked Dec. 28 at 11:21 PM

$KAPA

0 · Reply

Xtracked Dec. 28 at 11:16 PM

$KAPA

0 · Reply

JornelP Dec. 27 at 5:57 PM

1 · Reply

StrawberryRips Dec. 26 at 6:24 PM

A blessed year for most of my swings. Short algos ruined a lot of the momentum this year tho… God bless the bulls 🙏 $IXHL $NCNA $KAPA $GLSI

1 · Reply

Xtracked Dec. 26 at 3:43 PM

2 · Reply

Xtracked Dec. 26 at 1:15 PM

$KAPA Complain to the CEO....please Give him a call directly - 310 729 3371

1 · Reply

Stocktwits182182 Dec. 24 at 3:21 PM

$KAPA Soon, the only thing that's going to matter is how many shares you're holding.

1 · Reply

Tonyboner Dec. 23 at 7:54 PM

$KAPA This gets bought at some stage

0 · Reply

TB85 Dec. 23 at 7:13 PM

$KAPA Seems like Grinchen, came before Santa!🥴

0 · Reply

ezcheezie Dec. 23 at 1:50 PM

$KAPA Not the news we wanted. EOY right? ⌚👀

0 · Reply

Yummystocks Dec. 22 at 5:11 PM

$CAN $EHGO $KAPA $SRXH $HXHX bring some tension.give me more

0 · Reply

Xtracked Dec. 22 at 1:44 PM

$KAPA is giving its shareholders something for Xmas.... SMH 🙄

1 · Reply

TB85 Dec. 19 at 5:59 PM

$KAPA

2 · Reply

OrangeJoolius Dec. 19 at 5:45 PM

$KAPA Man this thing is thin, when it gets news here soon, watch out.

0 · Reply

ezcheezie Dec. 18 at 3:37 PM

$KAPA Some dark pool purchases? News after hours? Maybe premarket in the morning? 💪💪💪

0 · Reply

Yummystocks Dec. 18 at 3:37 PM

$EHGO $CAN $SRXH $KAPA bottom fishing

1 · Reply

OrangeJoolius Dec. 17 at 8:05 PM

$KAPA Got back in today, study results are due soon, and they are actively seeking a partner. May not be the very bottom, but it's close enough for me.

1 · Reply

Xtracked Dec. 17 at 4:53 PM

$KAPA Yes they will ... Notice the little error you pointed out, "moving soon", has been corrected on webpage. I haven't been BS ing you. It's coming SOON. I just don't know exactly when...if so , I'd already be rich or in jail. Holding through the pain 💪

1 · Reply

stockforce123 Dec. 17 at 3:48 PM

$KAPA People will find out soon here

0 · Reply

Xtracked Dec. 17 at 2:28 PM

$KAPA Congratulations,good news. Now let's have the great news 😁 Holding through all the quiet...by the time you find out, it'll be too late. Just remnants....This low float can and will move fast

1 · Reply

ezcheezie Dec. 17 at 1:47 PM

$KAPA https://www.businesswire.com/news/home/20251217192511/en/Kairos-Pharma-Wins-2025-Clinical-Trials-Arena-Research-and-Development-Excellence-Award-for-Advanced-Prostate-Cancer 👀👀👀🚀🚀🚀

0 · Reply

Stock_Catcher Dec. 17 at 1:15 PM

$KAPA Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer

1 · Reply

Market Cap	14.74M
Revenue (ttm)	0.00
Net Income (ttm)	-2.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	390,600
Avg Vol	203,318
Day's Range	N/A - N/A
Shares Out	20.82M
Stochastic %K	13%
Beta	2.20
Analysts	Strong Sell
Price Target	$8.33